Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosis
Lourdes Encinas, Si-Yang Li, Joaquin Rullas-Trincado, Rokeya Tasneen, Sandeep Tyagi, Heena Soni, Adolfo Garcia-Perez, Jin Lee, del Rio Rubén González, Jaime De Mercado, Verónica Sousa, Izidor Sosič, Stanislav Gobec, Alfonso Mendoza-Losana, Paul J. Converse, , Eric L. Nuermberger
This study evaluates direct inhibitors of InhA (DIIs) for tuberculosis treatment, showing their efficacy comparable to isoniazid and their potential in new drug regimens.
bioRxiv · Mar 8, 2024 · PreprintPharmacology & Toxicology